Prasinezumab

• UNSPSC Description:

  Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research[1].

• Target Antigen:

  α-synuclein

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/prasinezumab.html

• Purity:

  99.90

• Solubility:

  10 mM in DMSO

• Smiles:

  [Prasinezumab]

• References & Citations:

  [1]Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 2

• CAS Number:

  1960462-19-4